These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 32394761)

  • 41. Prediction of axillary response by monitoring with ultrasound and MRI during and after neoadjuvant chemotherapy in breast cancer patients.
    Eun NL; Son EJ; Gweon HM; Kim JA; Youk JH
    Eur Radiol; 2020 Mar; 30(3):1460-1469. PubMed ID: 31802216
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Surgery following neoadjuvant chemotherapy for HER2-positive locally advanced breast cancer. Time to reconsider the standard attitude.
    Debled M; MacGrogan G; Breton-Callu C; Ferron S; Hurtevent G; Fournier M; Bourdarias L; Bonnefoi H; Mauriac L; Tunon de Lara C
    Eur J Cancer; 2015 Apr; 51(6):697-704. PubMed ID: 25704790
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The use of ultrasound in the clinical re-staging of the axilla after neoadjuvant chemotherapy (NACT).
    Peppe A; Wilson R; Pope R; Downey K; Rusby J
    Breast; 2017 Oct; 35():104-108. PubMed ID: 28704697
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of Discordance in Primary Tumor and Lymph Node Response After Neoadjuvant Therapy in Breast Cancer.
    Fleming CA; McCarthy K; Ryan C; McCarthy A; O'Reilly S; O'Mahony D; Browne TJ; Redmond P; Corrigan MA
    Clin Breast Cancer; 2018 Apr; 18(2):e255-e261. PubMed ID: 29246703
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic factors affecting locoregional recurrence in patients with stage IIIB noninflammatory breast cancer.
    Gülben K; Berberoğlu U; Cengiz A; Altınyollar H
    World J Surg; 2007 Sep; 31(9):1724-1730. PubMed ID: 17629742
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.
    Keam B; Im SA; Kim HJ; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Cho N; Moon WK; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    Breast Cancer Res Treat; 2009 Jul; 116(1):153-60. PubMed ID: 18787948
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Outcomes Following Neoadjuvant Chemotherapy for Breast Cancer in Women Aged 40 Years and Younger: Impact of Pathologic Nodal Response.
    Kozak MM; Jacobson CE; von Eyben R; Pollom EL; Telli M; Horst KC
    J Natl Compr Canc Netw; 2018 Jul; 16(7):845-850. PubMed ID: 30006427
    [No Abstract]   [Full Text] [Related]  

  • 48. Molecular types and neoadjuvant chemotherapy in patients with breast cancer- while molecular shifting is more common in luminal a tumors, the pathologic complete response is most frequently observed in her-2 like tumors.
    Salim DK; Mutlu H; Eryilmaz MK; Musri FY; Tural D; Gunduz S; Coskun HS
    Asian Pac J Cancer Prev; 2014; 15(21):9379-83. PubMed ID: 25422228
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sentinel lymph node biopsy is a reliable method for lymph node evaluation in neoadjuvant chemotherapy-treated patients with breast cancer.
    Koslow SB; Eisenberg RE; Qiu Q; Chen Z; Swistel A; Shin SJ
    Am Surg; 2014 Feb; 80(2):171-7. PubMed ID: 24480218
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sentinel lymph node biopsy in Chinese patients with large operable breast cancer (≥4 cm): A decade's experience from a single institution.
    Yang Y; He Y; Fan Z; Ouyang T
    Breast; 2017 Dec; 36():20-24. PubMed ID: 28869832
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Feasibility and Prognostic Effect of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Cytology-Proven, Node-Positive Breast Cancer.
    Park S; Lee JE; Paik HJ; Ryu JM; Bae SY; Lee SK; Kim SW; Nam SJ
    Clin Breast Cancer; 2017 Feb; 17(1):e19-e29. PubMed ID: 27495997
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tumour size is the only predictive factor of distant recurrence after pathological complete response to neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancers: a sub-study of EORTC 10994/BIG 1-00 phase III trial.
    Fei F; Messina C; Slaets L; Chakiba C; Cameron D; Bogaerts J; Bonnefoi H
    Eur J Cancer; 2015 Feb; 51(3):301-9. PubMed ID: 25578377
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tumor infiltrating neutrophil might play a major role in predicting the clinical outcome of breast cancer patients treated with neoadjuvant chemotherapy.
    Geng SK; Fu SM; Ma SH; Fu YP; Zhang HW
    BMC Cancer; 2021 Jan; 21(1):68. PubMed ID: 33446143
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Negative genic switch of HER-2 in the primary tumor instead of the synchronous metastatic nodal lesions after neoadjuvant chemotherapy in a patient with primary HER2-positive breast cancer.
    Chen HR; Wu YT; Yu QB; Yang YY; Wei YX; Li HY; Wu KN; Kong LQ
    World J Surg Oncol; 2017 Oct; 15(1):189. PubMed ID: 29052527
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
    Soliman H; Wagner S; Flake DD; Robson M; Schwartzberg L; Sharma P; Magliocco A; Kronenwett R; Lancaster JM; Lanchbury JS; Gutin A; Gradishar W
    Ann Surg Oncol; 2020 Mar; 27(3):765-771. PubMed ID: 31907749
    [TBL] [Abstract][Full Text] [Related]  

  • 56. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
    Gianni L; Pienkowski T; Im YH; Tseng LM; Liu MC; Lluch A; Starosławska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi GV; Magazzù D; McNally V; Douthwaite H; Ross G; Valagussa P
    Lancet Oncol; 2016 Jun; 17(6):791-800. PubMed ID: 27179402
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Response rate to neoadjuvant chemotherapy measured on imaging predicts early recurrence and death in breast cancer patients with lymph node involvements.
    Nagashima T; Sakakibara M; Kadowaki M; Suzuki TH; Yokomizo J; Ohki Y; Miyoshi T; Kazama T; Nakatani Y; Miyazaki M
    Acta Radiol; 2011 Apr; 52(3):241-6. PubMed ID: 21498357
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Predicting Axillary Response to Neoadjuvant Chemotherapy: Breast MRI and US in Patients with Node-Positive Breast Cancer.
    Kim R; Chang JM; Lee HB; Lee SH; Kim SY; Kim ES; Cho N; Moon WK
    Radiology; 2019 Oct; 293(1):49-57. PubMed ID: 31407967
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Analysis of the relevance between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer as well as its prognostic factors.
    Li F; Ma L; Geng C; Liu C; Deng H; Yue M; Ding Y; Wang X; Liu Y
    Pathol Res Pract; 2018 Aug; 214(8):1166-1172. PubMed ID: 29945816
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The impact of chemotherapy sequence on survival in node-positive invasive lobular carcinoma.
    Tamirisa N; Williamson HV; Thomas SM; Westbrook KE; Greenup RA; Plichta JK; Rosenberger LH; Hyslop T; Hwang ES; Fayanju OM
    J Surg Oncol; 2019 Aug; 120(2):132-141. PubMed ID: 31062375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.